)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Oncopeptides
Oncopeptides (ONCO) investor relations material
Oncopeptides Trading update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Trading update summary16 Jan, 2026
Financial performance and guidance
Q4 2025 net sales reached SEK 18.6 million, up 88% year-over-year and 125% versus 2024, with full-year 2025 sales totaling 71.2 million SEK.
Full-year sales of Pepaxti more than doubled in 2025, led by strong growth in Italy, but offset by slower uptake in Germany and a doctors' strike in Spain.
Sales in Spain were negatively impacted by a nationwide doctor strike, leading to results below projections and a shift in profitability expectations to 2027.
Cost optimization and strategic reviews are underway, especially in Germany, to align costs with revenue and support profitability at the country level in 2026.
Positive cash flow is now expected in 2027, later than previously anticipated.
Market dynamics and regional performance
Italy exceeded expectations with 90% regional access and strong demand, validating the clinical experience strategy.
Germany's growth was steady but limited by restricted access to healthcare professionals and increased competition, prompting a strategic focus on high-potential regions.
Spain achieved 100% access but suffered a significant sales decline due to a high-participation doctor strike and seasonal factors.
Greece showed positive momentum but experienced quarterly fluctuations due to centralized ordering and budget constraints.
Commercialization phases completed in several European countries, with approximately 55% of market potential reached and market exclusivity in Europe secured until 2037.
Expansion and partnership strategy
Active partnership discussions are ongoing for Central and Eastern Europe, with advanced talks and a non-binding licensing offer received in Japan.
Japan is seen as a promising market with centralized prescribers and a regulatory pathway similar to Italy's dynamics.
Global expansion includes licensing deals in South Korea and opportunistic partnerships in the MENA region, expected to contribute to 2026 revenues.
Nordic expansion is challenged by small market size and complex reimbursement processes, with ongoing efforts in Norway, Sweden, and Finland.
Partnerships are being pursued for market access and regulatory processes in various regions.
Impact of cash flow delay on operations
How will Germany achieve country-level profitability?
Timeline for Japan licensing deal finalization?
Impact of Spain strike on 2027 cash flow target?
Germany: How will focus areas drive 2026 profitability?
Japan partnership: What are the final hurdles?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Oncopeptides earnings date
Q4 202519 Feb, 2026
Oncopeptides
Next Oncopeptides earnings date
Q4 202519 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage